By IDSE News Staff
The FDA approved cefepime-enmetazobactam (FPE; Exblifep, Allecra Therapeutics) to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years of age and older.
The agency’s approval was supported by clinical data that demonstrated FPE’s effectiveness against antimicrobial resistance in gram-negative bacteria, especially resistance mediated by both extended-spectrum beta-lactamases (ESBLs) and AmpC. This included results